Solid-phase synthesis and evaluation of libraries of substituted 4,5-dihydropyridazinones as vasodilator agents

Journal of Pharmacy and Pharmacology

Volumn 56, Issue 8, 2004, Pages 1029-1037

  Gouault, Nicolas ^a   Martin Chouly, Corinne A E ^a   Lugnier, Claire ^b   Cupif, Jean François ^a   Tonnelier, Amaury ^a   Feger, Frédéric ^a   Lagente, Vincent ^a   David, Michèle ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2,2 DIETHOXYETHYLAMINO) 2,6 DIMETHYL 4,5 DIHYDROPYRAZIN 2(2H) ONE; 4 (2,2 DIETHOXYETHYLAMINO) 6 METHYL 4,5 DIHYDROPYRAZIN 2(2H) ONE; 4 [4 (FLUOROPHENYL)PIPERAZIN 1 YL] 2,6 DIMETHYL 4,5 DIHYDROPYRAZIN 3(2H) ONE; 4 [4 (FLUOROPHENYL)PIPERAZIN 1 YL] 6 METHYL 4,5 DIHYDROPYRAZIN 3(2H) ONE; 4,5 DIHYDRO 3(2H) PYRIDAZINONE DERIVATIVE; 4,5 DIHYDRO 6 [4 (1H IMIDAZOL 1 YL)PHENYL] 5 METHYL 3(2H) PYRIDAZINONE; 4,5 DIHYDRO 6 [4 (4 PYRIDYLAMINO)PHENYL] 3(2H) PYRIDAZINONE; 6 (4 BENZYLPIPERAZIN 1 YLMETHYL) 4,5 DIHYDROPYRAZIDIN 3(2H) ONE; 6 (4 CYCLOHEXYLPIPERAZIN 1 YLMETHYL) 2 METHYL 4,5 DIHYDROPYRAZIDIN 3(2H) ONE; 6 (4 CYCLOHEXYLPIPERAZIN 1 YLMETHYL) 4,5 DIHYDROPYRAZIDIN 3(2H) ONE; 6 (4 PHENYLPIPERAZIN 1 YLMETHYL) 2 METHYL 4,5 DIHYDROPYRAZIDIN 3(2H) ONE; 6 (4 PHENYLPIPERAZIN 1 YLMETHYL) 4,5 DIHYDROPYRAZIDIN 3(2H) ONE; 6 [4 (FLUOROPHENYL)PIPERAZIN 1 YLMETHYL] 2 METHYL 4,5 DIHYDROPYRAZIN 3(2H) ONE; 6 [4 (FLUOROPHENYL)PIPERAZIN 1 YLMETHYL] 6 METHYL 4,5 DIHYDROPYRAZIN 3(2H) ONE; CYCLIC AMP; ESTER DERIVATIVE; HYDRAZINE; ISOENZYME; METHYLHYDRAZINE; MILRINONE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PIMOBENDAN; PIPERAZINE DERIVATIVE; POLYMER; PYRIDAZINONE DERIVATIVE; QUINOLINE DERIVATIVE; RESIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASODILATOR AGENT;

AORTA; ARTICLE; CHEMICAL REACTION; CONTROLLED STUDY; CORONARY ARTERY DILATATION; CYCLIZATION; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG SYNTHESIS; HEART FAILURE; INOTROPISM; ISOLATION PROCEDURE; MOLECULAR LIBRARY; NONHUMAN; RAT; SOLID; VASCULAR SMOOTH MUSCLE; VASODILATATION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; AORTA; MALE; MUSCLE, SMOOTH, VASCULAR; PHOSPHODIESTERASE INHIBITORS; PYRIDAZINES; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP; VASODILATION; VASODILATOR AGENTS;

EID: 4344613642     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357043905     Document Type: Article

References (22)

1. Balkenhohl, F., Bussche-Hünnefeld, C., Lansky, A. Zechel, C. (1996) Combinatorial synthesis of small organic molecules. Angew. Chem. Int. Ed. Engl. 35: 2289-2237
2. Barnes, P. J. (2000) New directions in allergic diseases: mechanism-based anti-inflammatory therapies. J. Allergy Clin. Immunol. 106: 5-16
3. Bowman, P., Haikala, H., Paul, R. J. (1999) Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J. Pharmacol. Exp. Ther. 288: 316-325
4. Combs, D. W., Rampulla, M. S., Bell, S. C., Klaubert, D. H., Tobia, A. J., Falotico, R., Haertlein, B., Lakas-Weiss, C., Moore, J. B. (1990) 6-Benzoxaninylpyridazin-3-ones: potent, long-acting positive inotrope and peripheral vasodilator agents. J. Med. Chem. 33: 380-386
5. Corbin, J. D., Francis, S. H., Webb, D. J. (2002) Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology 60: 4 11
6. Giembycz, M. A. (2000) Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here? Drugs 59: 193-212
7. Gouault, N., Cupif, J. F., Picard, S., Lecat, A., David, M. (2001) Synthesis of diverse 4,5-dihydro-3(2H)-pyridazinones on Wang resin. J. Pharm. Pharmacol. 53: 981-985
8. Gouault, N., Cupif, J. F., Amoros, M., David, M. (2002) Expedient method for the solid-phase synthesis of some 4-substituted-4,5-dihydropyridazin-3(2H)-ones. J. Chem. Soc., Perkin Trans. 120: 2234-2236
9. Gruhn, N., Nielsen-Kudsk, J. E., Theilgaard, S., Bang, L., Olesen S.-R., Aldershvile, J. (1998) Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium sensitizing properties. J. Cardiovasc. Pharmacol. 31: 741-749
10. Hall, D. G., Manku, S., Wang, F. ( 2001) Solution- and solid-phase strategies for the design, synthesis, and screening of libraries based on natural product templates: a comprehensive survey. J. Comb. Chem. 3: 125-150
11. Kato, K. (1997) Clinical efficacy and safety of pimobendan in treatment of hearth failure - experience in Japan. Cardiology 88: 28-36
12. Ley, S. V., Baxendale, I. R. (2002) New tools and concepts for modern organic synthesis. Nat. Rev. Drug Discov. 1: 573-586
13. Lugnier, C., Schoeffer, P., Le Bec, A., Strouthou, E., Stoclet, J. C. (1986) Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem. Pharmacol. 35: 1743-1751
14. MacDonald, S. F. (1974) Methyl 5-bromolevulinate. Can. J. Chem. 52: 3257-3258
15. Nakamura, T., Houchi, H., Minami, A., Sakamoto, S., Tsuchiya, K., Niwa, Y., Minakuchi, K, Nakaya, Y. (2001) Endothelium-dependent relaxation by cilostazol, a phosphodiesterase III inhibitor, on rat thoracic aorta. Life Sci. 69: 1709-1715
16. Pagel, P. S., Hettrick, D. A., Warltier, D. C. (1996) Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs. Br. J. Pharmacol. 119: 609-615
17. Polson, J. B., Strada, S. J. (1996) Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu. Rev. Pharmacol. Toxicol. 36: 403 427
18. Porter, N. A., Scott, D. M., Rosenstein, I. J., Giese, B., Veit, A., Zeitz, H. G. (1991) Stereoselective intramolecular radical additions to amide-substituted alkenes. J. Am. Chem. Soc. 113: 1791-1799
19. Silver, P. J. (1989) Biochemical aspects of inhibition of cardio-vascular low (Km) cyclic adenosine monophosphate diesterase. Am. J. Cardiol. 63: 2A-8A
20. Sircar, I., Bobowski, G., Bristol, J. A., Weishaar, R. E., Evans, D. B. (1986) Cardiotonic agents. 3. Synthesis and biological activity of novel 6-(substituted 1H-imidazol-4(5)-yl)-3(2H)-pyridazinones. J. Med. Chem. 29: 261 267
21. Vegh, A., Papp, J. G., Udvary, E., Kaszala, K. (1995) Hemodynamic effects of calcium-sensitized agents. J. Cardiovasc. Pharmacol. 26: S20-S31
22. Young, J. B. (2001) New therapeutic choices in the management of acute congestive heart failure. Rev. Cardiovasc. Med. 2 (Suppl. 2): S19-S24